Self-reported symptoms as predictors of SARS-CoV-2 infection in the general population living in the Amsterdam region, the Netherlands.

Autor: Bosdriesz JR; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.; Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Ritsema F; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.; Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Leenstra T; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands., Petrignani MWF; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands., Bruisten SM; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.; Department of Medical Microbiology, Amsterdam Infection & Immunity Institute (AII), Amsterdam University Medical Center (UMC), Amsterdam, The Netherlands., Coyer L; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.; Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Schreijer AJM; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands., van Duijnhoven YTHP; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands., Schim van der Loeff MF; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.; Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Matser AA; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands.; Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2022 Jan 28; Vol. 17 (1), pp. e0262287. Date of Electronic Publication: 2022 Jan 28 (Print Publication: 2022).
DOI: 10.1371/journal.pone.0262287
Abstrakt: Introduction: Most COVID-19 symptoms are non-specific and also common in other respiratory infections. We aimed to assess which symptoms are most predictive of a positive test for SARS-CoV-2 in symptomatic people of the general population who were tested.
Methods: We used anonymised data of all SARS-CoV-2 test results from the Public Health Service of Amsterdam from June 1,2020 through August 31, 2021. Symptoms were self-reported at time of requesting a test. Multivariable logistic regression models with generalized estimating equations were used to identify predictors of a positive test. Included symptoms were: cough, fever, loss of smell or taste, muscle ache, runny nose, shortness of breath, and throat ache; adjustments were made for age and gender, and stratification by month.
Results: Overall, 12.0% of 773,680 tests in 432,213 unique individuals were positive. All symptoms were significantly associated with a positive test result, the strongest positive associations were: cough (aOR = 1.78, 95%CI = 1.75-1.80), fever (aOR = 2.11, 95%CI = 2.07-2.14), loss of smell or taste (aOR = 2.55, 95%CI = 2.50-2.61), and muscle ache (aOR = 2.38, 95%CI = 2.34-2.43). The adjusted odds ratios for loss of smell or taste slightly declined over time, while that for cough increased.
Conclusion: Cough, fever, loss of smell or taste, and muscle ache appear to be most strongly associated with a positive SARS-CoV-2 test in symptomatic people of the general population who were tested.
Competing Interests: The authors have read the journal’s policy and have the following competing interests: MFSvdL received research funding from Sanofi-Pasteur MSD; he is a co-investigator in a Sanofi-Pasteur-MSD HPV vaccine trial; he sat on a vaccine advisory board of GSK; his institution received in-kind contribution for an HPV study from Stichting Pathologie Onderzoek en Ontwikkeling (SPOO); his institution receives research funding from Janssen Infectious Diseases and Vaccines. There are no patents, products in development or marketed products associated with this research to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The other authors declare no conflicts of interest.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje